Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
1,569
Views
3
CrossRef citations to date
0
Altmetric
Hepatology

Cost-effectiveness of defibrotide for treatment of severe veno-occlusive disease: it is time for evidence based economic evaluations

Alois GratwohlDepartment of Hematology, Medical Faculty, University of Basel, Basel, SwitzerlandCorrespondence[email protected]
Pages 727-729 | Received 12 Apr 2021, Accepted 10 May 2021, Published online: 31 May 2021

References

  • Carcedo Rodriguez D, Chinea Rodriguez A, Garcia TE, et al. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain. J Med Econ. 2021;24(1):628–636.
  • Zhao Y, Feng HM, Qu J, et al. A systematic review of pharmacoeconomic guidelines. J Med Econ. 2018;21(1):85–96.
  • Ruutu T, Carreras E. Chapter 49. Hepatic complications. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Cham (CH): Springer; 2019.
  • Bonifazi F, Sica S, Angeletti A, et al. Veno-occlusive disease in HSCT patients: consensus- based recommendations for risk assessment, diagnosis, and management by the GITMO group. Transplantation. 2021;105(4):686–694.
  • Yang L, Qi J, Pan T, et al. Efficacy and safety of defibrotide for the treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Semin Thromb Hemost. 2019;45(8):767–777.
  • Niada R, Mantovani M, Prino G, et al. PGI2-generation and antithrombotic activity of orally administered defibrotide. Pharmacol Res Commun. 1982;14(10):949–957.
  • Defitelio, INN defibrotide (europa.eu) [Internet]. [cited 2021 Apr 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/defitelio-epar-product-information_en.pdf
  • Baron F, Deprez M, Beguin Y. The veno-occlusive disease of the liver. Haematologica. 1997;82(6):718–725.
  • Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol. 2000; May64(5):281–291.
  • U.S. Food and Drug Administration [Internet]. [cited 2021 Apr 12]. Available from: https://www.fda.gov/news-events/press-announcements/fdaapproves-first-treatment-rare-disease-patients-who-receive-stemcell-transplant-blood-or-bone
  • Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–1665.
  • Corbacioglu S, Cesaro S, Faraci M, et al. Defi brotide for prophylaxis of hepatic veno- occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379(9823):1301–1309.
  • Darrow JJ, Avorn J, Kesselheim AS. FDA Approval and Regulation of Pharmaceuticals, 1983-2018. J Am Med Assoc. 2020; 323(2):164–176.
  • Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020; 18:31.
  • Badia X, Vico T, Shepherd J, et al. Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019. Orphanet J Rare Dis. 2020;15(1):224.
  • Gratwohl A, Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy Europe (ISCT), the European Society for Blood, Marrow Transplantation (EBMT), Passweg J, Baldomero H, Orchard K, Kröger N, Snowden JA. Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy Europe (ISCT), the European Society for Blood, Marrow Transplantation (EBMT). Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. Br J Haematol. 2021;192(6):e151–e154.
  • Ruutu T, Gratwohl A, Niederwieser D, et al. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. Bone Marrow Transplant. 2017;52(3):357–362.
  • Gratwohl A, Schwendener A, Baldomero H, et al. Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica. 2010;95(4):637–643.
  • Gratwohl A, Mohty M, Apperley J. Chapter 2. The EBMT: history, present, and future. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. 7th edition. Cham (CH): Springer; 2019.
  • Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021. DOI:https://doi.org/10.1038/s41409-021-01227-8

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.